Skip to content

Study · Not a test of the peptide alone · 2019

5 results

IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy.

Miller E, Doshi A, Grøn R, Jódar E, Őrsy P, Ranthe MF, Sugimoto D, Tentolouris N, Viljoen A, Billings LK

Diabetes, obesity & metabolism28 Aug 2019Cited by 13 (Europe PMC)

PMID31385425 (opens in a new tab)PMCIDPMC6899651 (opens in a new tab)DOI10.1111/dom.13851 (opens in a new tab)PepBankPUB-31385425
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneRandomized controlled trialOther

    In adults with type 2 diabetes, IDegLira needed 1 injection per day against 3 or more with basal-bolus therapy.

    In plain wordsIn adults with type 2 diabetes, the insulin and liraglutide combination needed fewer daily injections than basal-bolus insulin.

    Peptide
    Liraglutide
    Outcome
    DecreaseNumber of injections per day
    Study

    n = 506

    Comparator
    Basal-bolus therapy (insulin glargine plus insulin aspart)
    Outcome group
    Patterns of use · Whole body

    Measurements

    Injections per day
    1 per day
    IDegLira
    Injections per day
    ≥ 3 per day
    basal-bolus

    Source sentences

    Summary
    fewer injections (1 vs ≥3 per day, respectively).
    1 context sentence
    Summary · context
    DUAL VII was a 26-week, open-label trial in which patients with uncontrolled type 2 diabetes who were using metformin and insulin glargine 100 units/mL (20-50 U) were randomized 1:1 to IDegLira (N = 252) or basal-bolus (insulin glargine U100 + insulin aspart ≤4 times/day) (N = 254).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneRandomized controlled trialOther

    In adults with type 2 diabetes, IDegLira needed fewer cumulative dose adjustments than basal-bolus therapy (16.6 vs 217.2).

    In plain wordsIn adults with type 2 diabetes, the insulin and liraglutide combination needed far fewer dose changes than basal-bolus insulin.

    Peptide
    Liraglutide
    Outcome
    DecreaseCumulative dose adjustments
    Study

    n = 506

    Comparator
    Basal-bolus therapy (insulin glargine plus insulin aspart)
    Outcome group
    Patterns of use · Whole body

    Measurements

    Cumulative dose adjustments
    16.6 adjustments
    IDegLira
    Cumulative dose adjustments
    217.2 adjustments
    basal-bolus

    Source sentences

    Summary
    were achieved with fewer cumulative dose adjustments (16.6 vs 217.2, respectively)
    1 context sentence
    Summary · context
    DUAL VII was a 26-week, open-label trial in which patients with uncontrolled type 2 diabetes who were using metformin and insulin glargine 100 units/mL (20-50 U) were randomized 1:1 to IDegLira (N = 252) or basal-bolus (insulin glargine U100 + insulin aspart ≤4 times/day) (N = 254).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, IDegLira gave significant improvements across all TRIM-D domains compared with basal-bolus therapy.

    In plain wordsIn adults with type 2 diabetes, patients on the insulin and liraglutide combination reported better treatment impact scores than those on basal-bolus insulin.

    Peptide
    Liraglutide
    Outcome
    IncreaseTRIM-D treatment-related impact
    Study

    n = 506

    Comparator
    Basal-bolus therapy (insulin glargine plus insulin aspart)
    Outcome group
    Quality of life · Whole body

    Source sentences

    Summary
    Patients treated with IDegLira experienced significant improvements across all TRIM-D domains compared with those undergoing basal-bolus therapy.
    2 context sentences
    Summary · context
    Patient-reported outcomes (Treatment-Related Impact Measure - Diabetes [TRIM-D] and Short Form-36 Health Survey version 2 [SF-36v2]) were collected at scheduled visits and change from baseline scores calculated.
    Summary · context
    DUAL VII was a 26-week, open-label trial in which patients with uncontrolled type 2 diabetes who were using metformin and insulin glargine 100 units/mL (20-50 U) were randomized 1:1 to IDegLira (N = 252) or basal-bolus (insulin glargine U100 + insulin aspart ≤4 times/day) (N = 254).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the SF-36v2 physical component summary improved in both arms with no significant difference between IDegLira and basal-bolus therapy.

    In plain wordsIn adults with type 2 diabetes, physical quality-of-life scores improved in both groups, with no clear difference between them.

    Peptide
    Liraglutide
    Outcome
    No significant changeSF-36v2 physical component summary
    Study

    n = 506

    Comparator
    Basal-bolus therapy (insulin glargine plus insulin aspart)
    Outcome group
    Quality of life · Whole body

    Source sentences

    Summary
    The SF-36v2 showed improvements in both treatment arms with no significant difference between arms in the physical component summary
    2 context sentences
    Summary · context
    Patient-reported outcomes (Treatment-Related Impact Measure - Diabetes [TRIM-D] and Short Form-36 Health Survey version 2 [SF-36v2]) were collected at scheduled visits and change from baseline scores calculated.
    Summary · context
    DUAL VII was a 26-week, open-label trial in which patients with uncontrolled type 2 diabetes who were using metformin and insulin glargine 100 units/mL (20-50 U) were randomized 1:1 to IDegLira (N = 252) or basal-bolus (insulin glargine U100 + insulin aspart ≤4 times/day) (N = 254).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, IDegLira gave a significant improvement in the SF-36v2 mental component summary compared with basal-bolus therapy.

    In plain wordsIn adults with type 2 diabetes, mental quality-of-life scores improved more with the insulin and liraglutide combination than with basal-bolus insulin.

    Peptide
    Liraglutide
    Outcome
    IncreaseSF-36v2 mental component summary
    Study

    n = 506

    Comparator
    Basal-bolus therapy (insulin glargine plus insulin aspart)
    Outcome group
    Quality of life · Mental health and mood

    Source sentences

    Summary
    there was a significant improvement in patients treated with IDegLira in the mental component summary (P = .0228
    2 context sentences
    Summary · context
    Patient-reported outcomes (Treatment-Related Impact Measure - Diabetes [TRIM-D] and Short Form-36 Health Survey version 2 [SF-36v2]) were collected at scheduled visits and change from baseline scores calculated.
    Summary · context
    DUAL VII was a 26-week, open-label trial in which patients with uncontrolled type 2 diabetes who were using metformin and insulin glargine 100 units/mL (20-50 U) were randomized 1:1 to IDegLira (N = 252) or basal-bolus (insulin glargine U100 + insulin aspart ≤4 times/day) (N = 254).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.